Docket #: S23-099
Massively Parallel Mixed Lymphocyte Reactions
Stanford researchers have developed technology enabling pooling and simultaneous testing of engineered T cells from multiple human donors. This invention increases scale and reduces costs for diagnostic, and pre-clinical development of engineered T cell therapies.
Engineered immune cell testing, particularly CAR-T cells, is costly and time-consuming. A major challenge is the inability to pool T cells from multiple donors due to mutual recognition as foreign cells. In this invention Stanford researchers have developed technology to be able to successfully pool and simultaneously test T cells from multiple human donors without adverse reactions between the T cells from different donors.
Stage of Development
In vitro
Applications
- Cell therapy development
- Cell therapy diagnostic
Advantages
- Scaleable
- Significantly cheaper and less resource intensive
Patent Status
Provisional patent application filed
Related Links
Patents
- Published Application: WO2025165786
Similar Technologies
-
Molecular Signature for Diagnosis of Chronic Fatigue, Long COVID, and Autoimmunity Conditions S23-075Molecular Signature for Diagnosis of Chronic Fatigue, Long COVID, and Autoimmunity Conditions
-
Biomarker for Osteoarthritis Detection S24-417Biomarker for Osteoarthritis Detection
-
Single-cell analysis in living humans to understanding ocular disease mechanisms S23-394Single-cell analysis in living humans to understanding ocular disease mechanisms